Literature DB >> 26324167

Electrophysiological characterization of human and mouse sodium-dependent citrate transporters (NaCT/SLC13A5) reveal species differences with respect to substrate sensitivity and cation dependence.

Ruud Zwart1, Polina M Peeva2, James X Rong2, Emanuele Sher2.   

Abstract

The citric acid cycle intermediate citrate plays a crucial role in metabolic processes such as fatty acid synthesis, glucose metabolism, and β-oxidation. Citrate is imported from the circulation across the plasma membrane into liver cells mainly by the sodium-dependent citrate transporter (NaCT; SLC13A5). Deletion of NaCT from mice led to metabolic changes similar to caloric restriction; therefore, NaCT has been proposed as an attractive therapeutic target for the treatment of obesity and type 2 diabetes. In this study, we expressed mouse and human NaCT into Xenopus oocytes and examined some basic functional properties of those transporters. Interestingly, striking differences were found between mouse and human NaCT with respect to their sensitivities to citric acid cycle intermediates as substrates for these transporters. Mouse NaCT had at least 20- to 800-fold higher affinity for these intermediates than human NaCT. Mouse NaCT is fully active at physiologic plasma levels of citrate, but its human counterpart is not. Replacement of extracellular sodium by other monovalent cations revealed that human NaCT was markedly less dependent on extracellular sodium than mouse NaCT. The low sensitivity of human NaCT for citrate raises questions about the translatability of this target from the mouse to the human situation and raises doubts about the validity of this transporter as a therapeutic target for the treatment of metabolic diseases in humans.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26324167     DOI: 10.1124/jpet.115.226902

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  A dynamic anchor domain in slc13 transporters controls metabolite transport.

Authors:  Ahlam Khamaysi; Sara Aharon; Hadar Eini-Rider; Ehud Ohana
Journal:  J Biol Chem       Date:  2020-03-09       Impact factor: 5.157

2.  The human longevity gene homolog INDY and interleukin-6 interact in hepatic lipid metabolism.

Authors:  Christian von Loeffelholz; Stefanie Lieske; Frank Neuschäfer-Rube; Diana M Willmes; Nathanael Raschzok; Igor M Sauer; Jörg König; Martin F Fromm; Paul Horn; Antonios Chatzigeorgiou; Andrea Pathe-Neuschäfer-Rube; Jens Jordan; Andreas F H Pfeiffer; Geltrude Mingrone; Stefan R Bornstein; Peter Stroehle; Christoph Harms; F Thomas Wunderlich; Stephen L Helfand; Michel Bernier; Rafael de Cabo; Gerald I Shulman; Triantafyllos Chavakis; Gerhard P Püschel; Andreas L Birkenfeld
Journal:  Hepatology       Date:  2017-06-26       Impact factor: 17.425

3.  Peptide Tags and Domains for Expression and Detection of Mammalian Membrane Proteins at the Cell Surface.

Authors:  Valeria Jaramillo-Martinez; Vadivel Ganapathy; Ina L Urbatsch
Journal:  Methods Mol Biol       Date:  2022

4.  Analysis of naturally occurring mutations in the human uptake transporter NaCT important for bone and brain development and energy metabolism.

Authors:  Stefan Selch; Anja Chafai; Heinrich Sticht; Andreas L Birkenfeld; Martin F Fromm; Jörg König
Journal:  Sci Rep       Date:  2018-07-27       Impact factor: 4.379

5.  Untargeted Metabolomics of Slc13a5 Deficiency Reveal Critical Liver-Brain Axis for Lipid Homeostasis.

Authors:  Sofia Milosavljevic; Kevin E Glinton; Xiqi Li; Cláudia Medeiros; Patrick Gillespie; John R Seavitt; Brett H Graham; Sarah H Elsea
Journal:  Metabolites       Date:  2022-04-14

6.  L-Arginine and Cardioactive Arginine Derivatives as Substrates and Inhibitors of Human and Mouse NaCT/Nact.

Authors:  Daniela B Surrer; Martin F Fromm; Renke Maas; Jörg König
Journal:  Metabolites       Date:  2022-03-22

7.  Model-Based Assessment of Plasma Citrate Flux Into the Liver: Implications for NaCT as a Therapeutic Target.

Authors:  Z Li; D M Erion; T S Maurer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.